Cardiac Glycosides 1785–1985: Biochemistry — Pharmacology — Clinical Relevance

Front Matter....Pages I-XVII
William Withering — The man and his work....Pages 1-10
Fruitful routes and blind alleys taken by digitalis therapy since its introduction by Withering....Pages 11-16
Therapeutic use of digitalis until the time of William Withering....Pages 17-18
The function of Na + ,K + -ATPase and its importance for drug action....Pages 19-25
Structural studies on the cardiac glycoside receptor....Pages 27-33
Isoenzymes of Na,K-ATPase identified by pyrithiamin....Pages 35-40
Interaction of cardiac glycosides with Na/K-ATPase in intact myocardium....Pages 41-47
The human red blood cell: A model for ouabain receptor regulation in the heart?....Pages 49-54
Binding and release of ouabain at low Mg 2+ in reconstituted human red blood cell ghosts....Pages 55-59
The ouabain receptor in the myocardium and conduction system of the sheep heart....Pages 61-68
Electrophysiological effects of cardiac glycosides....Pages 69-78
Electrophysiological assay of glycoside-induced sodium pump inhibition in isolated sheep heart Purkinje fibres at the onset of toxicity....Pages 79-86
Rat cardiac hypertrophy: contribution of heteregeneous digitalis receptor forms....Pages 87-92
Digitalis receptors in normal and hypertrophied rat hearts. Differential effects of a Ca 2+ free perfusion....Pages 93-98
Biphasic contractile response to ouabain: Species specific? Calcium dependent? Altered sensitivity?....Pages 99-108
The influence of α -tocopherol-nicotinate (Renascin ® ) on cardiac glycoside effects....Pages 109-117
On the connection between cardiac glycosides and calcium action....Pages 119-125
Biochemical basis for the targeted synthesis of cardiac glycosides with selective action....Pages 127-134
The “endogenous cardiac glycoside”....Pages 135-142
Endogenous digitalis, cardiodigin and other regulators of the sodium pump....Pages 143-155
Digitalis-like factors in plasma of healthy human adults....Pages 157-164
A Na + ,K + -ATPase inhibitor isolated from pig kidney....Pages 165-169
Cardiac glycoside-like effects of a bufadienolide extracted from Kalanchoe Daigremontiana....Pages 171-179
Positive inotropic agents: Different mechanisms of action....Pages 181-188
Significance of calcium ions in the regulation of myocardial contractility....Pages 189-194
Additive and non-additive positive inotropic effects in human and guinea-pig myocardium....Pages 195-205
The cardiac Na + /H + exchange system. Its role in inotropy....Pages 207-213
Evidence for pharmacodynamic differences between cardiac glycosides of different polarities....Pages 215-219
The positive inotropic action of mercury compounds on isolated heart muscle....Pages 221-227
Chronic pretreatment with amrinone or milrinone induces no tachyphylaxis in mammalian cardiac muscle....Pages 229-236
Left ventricular function after oral milrinone in patients with congestive heart failure. A hemodynamic and angiographic study....Pages 237-244
The importance of skeletal muscles as a distribution volume for digitalis glycosides in guinea-pigs and human subjects....Pages 245-255
Relevant metabolism of cardiac glycosides....Pages 257-262
The dihydrogenation of digoxin....Pages 263-268
Renal excretion and plasma levels of dihydrodigitoxin in volunteers and renally healthy and renally insufficient patients being treated with digitoxin....Pages 269-272
Enzymatic basis for digitoxin metabolism and possible drug interactions in man....Pages 273-279
Effect of quinidine on the inotropic effect of digoxin in isolated cat or guinea-pig papillary muscle....Pages 281-286
Quinidine decreases the intestinal secretion of digoxin and digitoxin in the guinea-pig....Pages 287-292
Quinidine-induced reduction of the biliary excretion of digoxin in patients....Pages 293-296
Role of the bile acid transport system in hepatocellular ouabain uptake....Pages 297-304
Distribution of digoxin, digitoxin and their cardioactive metabolites in human heart and kidney....Pages 305-313
Application of HPLC-DAD instead of the guinea-pig test for the quantitative determination of cardiac glycosides....Pages 315-321
Interaction between 16-acetyl-gitoxin and drugs....Pages 323-328
Digitoxin protein binding in patients on hemodialysis....Pages 329-335
The effect of physical exercise on the distribution and renal excretion of digoxin....Pages 337-342
Ouabain binding to erythrocytes from neonates, blood cord and pregnant women....Pages 343-346
Extracardiac effects of cardiac glycosides....Pages 347-356
Effects of digitalis on renal tubular sodium reabsorption....Pages 357-365
Ouabain-induced efflux of catecholamines and metabolites from blood vessels of normotensive and hypertensive dogs....Pages 367-376
Digoxin-specific antibody treatment of digitalis toxicity: Update....Pages 377-382
Kinetics of the Fab fragments of digoxin antibodies and of bound digoxin in patients with severe digoxin intoxication....Pages 383-388
Influence of tubular Na-K-ATPase activity on the development of hyperkalemia in digoxin intoxications....Pages 389-394
24-Hour Holter ECG in digoxin intoxicated patients....Pages 395-398
Clinically relevant interactions with cardiac glycosides....Pages 399-406
Importance of serum glycoside concentrations....Pages 407-416
Metabolic aspects of compensatory mechanisms in cardiac failure....Pages 417-428
Effects of digitalis glycosides on the systemic arterial and venous system: clinical importance in the pathophysiology of congestive heart failure....Pages 429-436
Attenuation of cardiac glycoside effects during long-term treatment....Pages 437-445
When to start digitalis?....Pages 447-453
Cardiotonic effect of digitalis in sinus rhythm during exercise....Pages 455-460
Digitalis treatment in pulmonary heart disease....Pages 461-469
Cardiac glycosides for paroxysmal atrial fibrillation?....Pages 471-475
Cardiac glycosides in anaesthesia....Pages 477-486
Effects of preoperative digitalisation on postoperative left heart performance and incidence of complications following hip surgery. First results of a prospective study....Pages 487-492
Digoxin therapy and mortality following confirmed or suspected myocardial infarction: Experience in the MILIS study....Pages 493-508
Improvement of ventricular function by treatment with β-methyldigoxin in patients with sinus rhythm after extended myocardial infarction: An exercise-radionuclide-ventriculography study....Pages 509-515
Effect of intravenous digoxin on left ventricular contractility at rest and during isometric exercise in intact and pharmacologically denervated heart....Pages 517-518
Low versus medium dosage digoxin therapy in patients with heart failure. A randomized, double-blind, cross-over study....Pages 519-525
The effects of digoxin and xamoterol in patients with moderate cardiac failure....Pages 527-530
The clinical, haemodynamic, and pharmacological consequences of withdrawal of digoxin after long-term treatment in patients with heart failure in sinus rhythm....Pages 531-533
New positive inotropic agents: Advantages and disadvantages....Pages 535-540
When should digitalis be discontinued?....Pages 541-548
Back Matter....Pages 549-552